# Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012

> **NIH NIH UM1** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $1,341,481

## Abstract

PROJECT SUMMARY
This supplement proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN)
research to be carried out at the NYU VTEU. We will participate in the implementation of in DMID protocol 21-
0012, “A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA
Vaccines.” This Phase 1/2 study will evaluate the safety, tolerability, immunogenicity of different SARS-CoV-2
vaccine delayed boost at >12 weeks. This study will be composed of two different cohorts:
1. A cohort of persons previously vaccinated with an EUA vaccine who will be boosted with a homologous or
heterologous vaccine strain on a homologous or a heterologous platform; and
2. A cohort of persons who are prospectively vaccinated with EUA standard dosing and who will be available
for rapid assessment of a heterologous boost at some point in the future.

## Key facts

- **NIH application ID:** 10411291
- **Project number:** 3UM1AI148574-02S2
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Mark Joseph Mulligan
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,341,481
- **Award type:** 3
- **Project period:** 2021-07-14 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10411291

## Citation

> US National Institutes of Health, RePORTER application 10411291, Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012 (3UM1AI148574-02S2). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10411291. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*